Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 24, 2023
-
Apr 24, 2023
-
Dec 7, 2021- 100% Disease Control Rate (DCR): 16 of 16 evaluable patients demonstrate tumor shrinkage
-
Nov 15, 2021- Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025
-
Oct 18, 2021- Former Chief Scientific Officer and Head of Tumor Biology at Pfizer will lead IDEAYA's research organization as Chief Scientific Officer
-
Aug 10, 2021- Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025
-
Jun 28, 2021‒ Observed plasma SAM reduction in each of the first two dose escalation cohorts of the IDE397 Phase 1 clinical trial, satisfying the clinical protocol threshold of approximately 60% or greater plasma S-adenosyl methionine (SAM) pharmacodynamic (PD) reduction to initiate IDE397 tumor biopsy cohort for evaluation of tumor PD markers
-
May 10, 2021- Completed enrollment of initial dose escalation cohort of the Phase 1 clinical trial evaluating IDE397, a potential best-in-class MAT2A inhibitor for MTAP-deletion patients
-
May 10, 2021- Observed early clinical efficacy in first cohort of darovasertib plus crizotinib combination with tumor reduction in 2 of 2 evaluable MUM patients, including a partial response in a 3L patient with a 54% tumor reduction who is awaiting a confirmatory scan
